Granted Patent B2

US 12,497,446 · App. 17/634,430 · Granted Dec 16, 2025

Inventors: Haichao Wang (Edison, NJ); Weiqiang Chen (Garden City, NY); Jian Hua Li (New York, NY); Kevin J. Tracey (Old Greenwich, CT)

Assignee: The Feinstein Institutes For Medical Research

C07K16/18A61P19/02A61P29/02A61P39/00A61K2039/505C07K2317/24C07K2317/76C07K2317/92

Abstract

Claims (73)

1 . An antibody or antigen-binding fragment thereof comprising

a) a heavy chain variable region comprising:

(SEQ ID NO: 21)

TDYMS,

(SEQ ID NO: 22)

AINSNGGTTYYPDTVKG, and

(SEQ ID NO: 23)

QVKNGLDY;

and a light chain variable region comprising:

(SEQ ID NO: 24)

RASQDISNYLN,

(SEQ ID NO: 25)

KTSRLHS, and

(SEQ ID NO: 26)

QQGNTLPPT;

or

b) a heavy chain variable region comprising:

(SEQ ID NO: 27)

SYYMS,

(SEQ ID NO: 28)

AINSNGGRTYYPDTVKG, and

(SEQ ID NO: 29)

QGKNGLDY;

and a light chain variable region comprising:

(SEQ ID NO: 30)

RASQDISNHLN,

(SEQ ID NO: 31)

YTSRLHS, and

(SEQ ID NO: 32)

QQGKTLPPT;

or

c) a heavy chain variable region comprising:

(SEQ ID NO: 33)

SSYMS,

(SEQ ID NO: 34)

AINNNGGTTYYPDTVKG, and

(SEQ ID NO: 35)

QGKNGLDY;

and a light chain variable region comprising:

(SEQ ID NO: 36)

RASQDIGNLLN,

(SEQ ID NO: 37)

YTSRLHS, and

(SEQ ID NO: 38)

QQANTLPPT;

or

d) a heavy chain variable region comprising:

(SEQ ID NO: 39)

SDYMS,

(SEQ ID NO: 40)

AINSNGGTTYYPDTVKG, and

(SEQ ID NO: 41)

QGKNGMDY;

and a light chain variable region comprising:

(SEQ ID NO: 42)

RASQDISNHLN,

(SEQ ID NO: 43)

YTSRLHS, and

(SEQ ID NO: 44)

QQGKTLPPT,

wherein the antibody or antigen-binding fragment thereof binds tetranectin.

2 . The antibody or fragment thereof of claim 1 , wherein framework regions of the light chain and/or the heavy chain are human framework regions.

3 . The antibody or fragment thereof of claim 2 , wherein framework regions of the light chain and the heavy chain are human framework regions.

4 . The antibody or antigen-binding fragment thereof of claim 1 , which has a human sequence Fc region.

5 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or fragment thereof is chimeric or humanized.

6 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or fragment thereof is selected from the group consisting of a monoclonal antibody, an scFv, an Fab fragment, an Fab' fragment, an F(ab)' fragment and a bispecific antibody.

7 . The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody is a humanized antibody and is an IgG1(λ) or an IgG2(λ).

8 . The antibody or antigen-binding fragment thereof of claim 1 , which inhibits interaction between a tetranectin that the antibody or antigen-binding fragmentit binds and an HMGB 1 .

9 . The antibody or antigen-binding fragment thereof of claim 1 , which inhibits cellular tetranectin uptake and/or tetranectin depletion in a subject when administered to the subject.

10 . An antibody or fragment thereof according to claim 1 , linked or conjugated to a therapeutic agent, an imaging agent or a detectable marker.

11 . The antibody or fragment thereof according to claim 10 , wherein the therapeutic agent is a cytotoxic drug, a radioactive isotope, an immunomodulator, or a second antibody.

12 . A method of treating sepsis or endotoxemia in a subject comprising administering an amount of an antibody of claim 1 , or a human tetranectin-binding fragment thereof, effective to treat sepsis or endotoxemia in a subject.

13 . A method of treating neuropathic pain in a subject comprising administering an amount of an antibody of claim 1 , or a human tetranectin-binding fragment thereof, effective to effective to treat neuropathic pain in a subject.

Assignments (1)

Continuity (2)

References Cited (19)